Shares last traded at $0.45 which is significantly higher than the 50 day moving average of $0.39 and which is a tad under the 200 day moving average of $0.48. The 50 day moving average was up by +15.790% and the 200 day average moved down $-0.03. Trading was light with 49K shares changing hands by the end of trading on Tuesday. Shares saw a steep decrease in trading volume of 84.81% under the normal average daily volume.
Investors are more bullish on Tenax Therapeutics, Inc. recently if you look at the downtick in short interest. The company had a fall in short interest of -18.52% as of the latest report on September 29, 2017. Short shares decreased 292,262 over that timeframe. Days to cover increased from 4.0 to 5.0 and the percentage of shorted shares is 0.05% as of September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (TENX). As of quarter end Bank Of NEW York Mellon Corp had bought 16,077 shares growing its stake by 601.9%. The value of the investment in Tenax Therapeutics, Inc. increased from $2,000 to $14,000 a change of $12,000 quarter to quarter. Citadel Advisors LLC augmented its holdings by buying 5,890 shares an increase of 17.0%. Citadel Advisors LLC now controls 40,528 shares valued at $30,000. The value of the position overall is up by 57.9%.
As of the end of the quarter Creative Planning had acquired a total of 1,000 shares growing its holdings by 100.0%. The value of the investment in (TENX) went from $1,000 to $1,000 a change of 0.0% quarter over quarter. Tower Research Capital LLC (trc) added to its ownership by buying 11,762 shares an increase of 916.0% as of 06/30/2017. Tower Research Capital LLC (trc) owns 13,046 shares with a value of $10,000. The total value of its holdings increased 233.3%.
As of the last earnings report the EPS was $-1.44 and is expected to be $-0.36 for the current year with 28,236,000 shares now outstanding. Next quarter’s EPS is forecasted at $-0.08 and the next full year EPS is projected to be $-0.28.
Tenax Therapeutics, Inc., launched on April 17, 2008, is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Business’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions..